brusatol has been researched along with Cancer of Endometrium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Feng, Y; Fu, Y; Hu, M; Huang, B; Li, J; Liao, H; Qin, Z; Sun, D; Wang, Y; Wei, Y; Wu, S; Yu, J; Zhang, Q; Zhang, Z; Zheng, W; Zhu, H | 1 |
| Chambers, SK; Guo, D; Liao, H; Park, JY; Wang, Y; Yi, X; Zhang, D; Zhang, Z; Zheng, W; Zheng, Y | 1 |
2 other study(ies) available for brusatol and Cancer of Endometrium
| Article | Year |
|---|---|
Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism.
Topics: Animals; DNA-Binding Proteins; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Mice; Mixed Function Oxygenases; NF-E2-Related Factor 2; Progesterone; Progestins; Proto-Oncogene Proteins | 2022 |
Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Topics: 20-Hydroxysteroid Dehydrogenases; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cell Line; Cell Proliferation; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endometrium; Female; Humans; Medroxyprogesterone Acetate; Metformin; NF-E2-Related Factor 2; Progestins; Quassins; RNA Interference; RNA, Small Interfering | 2016 |